Full Breakdown
$3,000 Katalyst EMS Suit: A First-Hand Test, Company Response, and Industry Debate
7/13/2026, 7:53:53 PM
Core Event
In 2025 the author purchased a Katalyst electro-muscle stimulation (EMS) fitness suit for $3,000. The suit requires wet electrode pads, a battery pack, and an app that delivers timed electrical pulses during squats, lunges and other movements. After a month of use the author experienced prolonged pins-and-needles, numbness, cold-induced sneezing, and an inability to resume rowing or swimming. The suit was returned, and the experience sparked a broader discussion about the technology’s efficacy and safety.
Background & Context
Katalyst markets its EMS suit as a way to “supercharge” workouts, promising a two-hour strength session in twenty minutes. The company is FDA-cleared as a Class II medical device, meaning it may be sold but is not FDA-approved for universal use. Founder Bjoern Woltermann allegedly took orders from more than 1,000 customers without delivering suits, leading to two bankruptcies. In 2025 CEO Brendan Kennedy, through his firm Mont y Mer, acquired Katalyst and claimed to have resolved production delays.
Key Figures & Groups
- Brendan Kennedy – CEO of Katalyst, former Mont y Mer executive.
- Bjoern Woltermann – Founder of Katalyst, former CEO.
- AustinAfter40 – YouTuber who documents EMS training, reports muscle gains.
- Casey Johnston – Newsletter author of *She’s a Beast*, critic of EMS suits.
- 404 Media staff – Emanuel Maiberg, Sam Cole, Jason Koebler (colleagues who commented on the author’s experience).
Data & Statistics
- Retail price: $3,000 per suit.
- FDA classification: Class II (moderate-risk) device, cleared but not approved.
- Reported user outcomes: AustinAfter40 claims 10 pounds of muscle in a few months, rising to 20 pounds; the author reports persistent sensory side effects lasting days.
Official Statements & Responses
Kennedy told the author that prolonged pins-and-needles were “extremely abnormal.” He explained that Katalyst’s FDA clearance permits market entry but does not constitute a safety endorsement for all users. Kennedy also described his 2025 acquisition of the company, noting that he “went around the world meeting with different suppliers to produce those original 1,000 suits” and that inventory issues have been “sort of solved.”
Criticism & Opposition
Casey Johnston called the suit “definitely in no way a replacement or even effective complement to strength training,” warning that it could impede learning proper movement form. She likened Katalyst to the 1949 Relaxacisor, labeling it “the biggest scam I’ve ever seen.” On the Katalyst subreddit, users have complained about inconsistent intensity ratings across competing EMS brands and about variable customer-service experiences.
Conflicting Reports & Gaps
Positive testimonials—such as AustinAfter40’s claim of significant muscle and bone-density gains—contrast sharply with the author’s adverse sensory effects and inability to maintain other exercise routines. The industry lacks standardized intensity metrics, making it difficult to compare Katalyst’s “200” rating with those of rivals like TitanBody or VisionBody. No independent clinical trials are cited in the available material.
Verbatim Quotes
- “More water is better,” — Brendan Kennedy, CEO
- “I'd been trying to go back to the gym a dozen times over the preceding 2-3 years with no luck. The time savings/mental ease of EMS training really is a blessing,” — AustinAfter40, YouTuber
- “My bone density has increased significantly, body fat has lowered, and back pain I've dealt with much of my life is now a distant memory,” — AustinAfter40, YouTuber
- “This suit looks like the biggest scam I’ve ever seen,” — Casey Johnston, Newsletter author
- “Legit you are the craziest person I know,” — Emanuel Maiberg, 404 Media colleague
What’s Next
Katalyst has announced that inventory shortages are resolved, but no further product updates or independent safety studies have been disclosed. Users considering EMS technology are advised to weigh anecdotal benefits against reported side effects and the lack of standardized performance metrics.
